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Breast cancer is the most common cancer among the women and makes up one-
third of cancers. Telomerase enzyme is a ribonucleoprotein with reverse transcriptase
activity that adds TTAGGG repeated sequences to the ends of the chromosomes. The
expression of the catalytic subunit of the enzyme (hTERT) in cancer cell lines and different
human tumors is shown. So, in this study, the proliferation of copies of the hTERT gene
in primary breast cancer was studied. Forty five Paraffin tissue samples from breast
cancer patients and forty five Paraffin tissue samples from  breast non-neoplastic patients
was provided from Ardabil Imam Khomeini Hospital’s Pathology section and DNA samples
were extracted with phenol-chloroform manually , then Real Time PCR was done with
hTERT Forward, and Reverse primers and GAPDH Forward, and Reverse. The tumor
sample was compared with the non- tumor one to investigate proliferation of copies of
the hTERT gene as a prognostic indicator in patients with primary breast cancer. Real
time PCR curve analysis for hTERT and GAPDH genes in tumor samples compared with
non-tumor samples showed that, there is no statistical deference’s between them (p=0.322).
The point of the best cut-off value was at >18.1 where sensitivity was 60 and specificity
was 58. The area under the ROC curve (AUC) was 0.555. For data analysis Spss statistical
software was used. Our current studies on results of amplification hTERT gene, in
comprising tumors samples with non-tumors is indication of early prognosis in primary
breast cancer patients. While, amplification of hTERT gene  in breast cancer patients
compared to the control group indicates that there is no statistical deference’s between
them and it  couldn’t be considered as prognosis factor for the primary breast cancer
patients. According to conducted  research it could be suggested that the hTERT gene may
be promoted through telomerase activity, but increasing the copy number in various
tumor cell line is not always dependent on telomerase activity and  it likely could have
an independent activity.
Keywords: Breast cancer, Telomerase, hTERT gene.
Breast cancer is the most common
malignant disease in women all over the world and
constitutes one-third of cancers  and after lung
cancer is considered the second leading cause of
cancer mortality in women1,2.
This disease is increased in Iran and since
1999 has the first country rank among recorded
cancers3, 4. Due to lack of organized screening and
training programs for initial and early detection of
breast cancer in Iran, about 70 % of Iranian women
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are diagnosed in dangerous stages of the disease5.
According to the cancer registration, breast cancer
in Ardabil is the most common one, following
esophagus and stomach cancers6 .  In human and
vertebrates, telomere is composed of double
strands with six repeated sequences, which
includes G -rich single-stranded overhang at the  3
‘ end. Telomere protects the end of chromosome
from breakage of the uncapped DNA,
recombination, fusion2,7,8
Due to the existence of a specific structure
at the end of the chromosome , DNA polymerase
enzyme is unable to complete replication of the
(End replication problem) end of the 3' lagging
strand. As a result, in every cell division, the human
telomere loses 50 to 200 bp.
Telomerase enzyme is a ribonucleoprotein
complex of telomere-specific reverse transcriptase
activity that uses an RNA template for adding
TTAGGG repeated sequences to the ends of the
chromosomes, and compensates for the loss of
the telomere length. So telomeres are replicated
by the telomerase enzyme9-15 .
Human telomerase enzyme activity is
composed of the human telomerase reverse
transcriptase (hTERT), human telomerase RNA
(hTR) and Dyskryn16.
Telomerase enzyme activity does not exist
in normal somatic cells, but It  is  seen  in 85 % - 90
% of human cancers, including more than 95 %  of
breast cancers, which is essential for continued
proliferation17. A limited number of cancers (15%)
preserve telomeres through recombination
mechanism with an alternative of telomere length
(ALT)18.
hTERT is expressed only in the telomerase
cells and is not expressed in differentiated cells19,20.
hTERT gene will amplify abundantly in human
tumors and tumor cell lines. This result implies that
an increase in copy numbers of hTERT gene, can
be involved in the regulation of telomerase
expression in the immortalized cells21,22. It is also
shown that hTERT is a decisive factor for
controlling telomerase activity20,23,24,25.
Reproduction of the catalytic subunit of
the enzyme (hTERT) in cancer cell lines and
different human tumors is shown. So, in this study,
the proliferation of copies of the hTERT gene in
primary breast cancer was studied.
MATERIALS   AND  METHOD
Forty five breast cancer formalin fixed
paraffin embedded (FFPE) specimens obtained from
the Department of surgery, Imam Hospital, Ardabil,
Iran. All patients signed detailed consent forms
before the study was conducted. The experimental
samples were pre-made on standard slides with 5
micron thick FFPE tissues using the standard
method by the Department of Pathology, Imam
Hospital.
3-5 slices of 5 micron from selected
samples placed in the 1.5 ml micro- tube and DNA
samples were extracted with phenol-chloroform
manually with using  xylol, ethanol, Layzyz buffer
, proteinase K, phenol saturated, chloroform -
isoamyl alcohol, sodium acetate , isopropanol and
the finally  50 micro- liter of distilled water added.
Then the sample for hTERT gene put
through  PCR, .For each process, 120 ¼l of buffer10
X, 36 ¼l of Mgcl2, 24 ¼l of dNTPs, 1 ¼l of primers
Forward (F) and Reverse (R), 0.1 ¼l of the enzyme
Taq DNA polymerase and 2 ¼l of DNA was used.
Sequences of primers used for F =
5„AGTGGAGACAGGCGCAT3„and R =5„
ATGGTGAGTGCTACATGGTGA3„.
Samples that were put through PCR
processed in the beginning at 95ÚC for 30 min,
then 35 cycles of 95ÚC for  30 sec, 35 cycles of 56Ú
C for 30 sec, 35 cycles of 72ÚC for 30 sec  , and
finally at 72ÚC for 7 min. PCR products were
electrophoresed at 0.01 agarose gel.
Then all of the samples in addition to
hTERT gene for GAPDH gene with  primer
sequences  F = 5´CTCTCTGCTCCTCCTGTTCGAC
3´ and R =5´TGAGCGATGTGGCTCGGCT 3´ were
gone through Real Time PCR process. Forty five
tumor samples and forty five non-tumor samples
were compared to increased amplification of hTERT
gene are reviewed as a prognostic marker for the
Primary breast cancer patients.
Samples were put through  Real Time PCR
in the beginning at 50ÚC for 2 min , then at 95ÚC
for 10 min, 60 cycles of 95ÚC for 15 sec and finally
60 cycles of 60ÚC 1 min.
RESULTS
In this experiment , Forty five paraffin-
embedded tumor samples from breast cancer
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Fig. 1. The curve increased amplification of hTERT gene in samples from patients and control group in the
experimental Real time PCR. The amount of fluorescence emitted increased during the cycle of the of increased PCR
products amounts
Table 1. hTERT  gene amplification in cancer and
control group
hTERT >= 18.2 <18.2 Total
control group 18 (40%) 27 (60%) 45 (100%)
Cancer group 26(57.8%) 19 (42.2%) 45 (100%)
Total 44 (100%) 46 (100%) 90 (100%)
P=0.092
Fig. 2. Amplification of  hTERT gene in breast cancer
patients compared to the Control group indicates that,
there is no statistical association existed between them.
Fig. 3. Boxplot diagram age group indicates  that there
is  no deferences between two age groups (P=0.261)
patients and 45 paraffin tissue samples from control
group was provided and investigations were
carried out on them , the results are as follows .
After the DNA tumor and non- tumor
samples was extracted, PCR was performed to
ensure the absence of primer dimmer. Then the
PCR products were analyzed by gel
electrophoresis.
To check the purity of the DNA extracted
from nano- drop device was used. Absorbance
reading DNA, extracted DNA quality can be
achieved. Relative absorbance (Optical Density:
OD) DNA at wavelengths 260 to 280 nm was
measured. Higher OD at wavelengths 280/260 of
1.8 is an indicator of DNA purity . Different
concentrations of DNA samples, using the formula
C1.V1 = C2.V2 Nanodrop apparatus were identical
and were given 20 ng micro liter5.
Quantification increased amplification of
hTERT and GAPDH gene in breast cancer patients
compared with those without tumor was performed.
Real time PCR curves amplification of hTERT gene
in tumor and non- tumor samples, is shown in Figure
1.
hTERT amplification in 19 of Cancer
patients is less than 18.2 (%42.2) and in 26 of them
it is more than 18.2. (%57.8). hTERT amplification
in 27 patient from control group is less than 18.2
(%60)  and in 18 of those patients it is more than
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Fig. 4. hTERT boxplot diagram according to stage which
indicates that there is no sign of  statistical deference
(P=0.1)
Table 2. The condition of the stages
Frequency Percent




Fig. 5. The point of the best cut-off value was at >18.2
where sensitivity was 60 and specificity was 57.8
Fig. 6. Amplification of  hTERT diagnostic accuracy.
ROC curve analysis showing the diagnostic performance
of ratio for  discriminating patients with breast cancer
from controls (AUC=0.555)
18.2 (%40), which proves that there is no deference
with regard to amplification of hTERT between
control groups and Cancer Patients. Amplification
of hTERT gene in cancer and control group, is
shown Table 1.
The average numbers of hTERT on group
of Cancer Patient are 19 ± 4.8 and in control group
these numbers were 18.6 ± 4 which show that, there
is no visible deference in computed average
numbers between control group with] group of
cancer patients (Figure 2). In cancer patients and
control groups the OR=1.4 and the confidence
interval (CT) is equal with 0.9 – 2.2 which shows
no noticeable deference between two groups.
Average numbers of hTERT  in over 50
years old age groups are estimated 20 ± 7.6  and in
under 50 years old age groups are 18 ± 3.7 which
indicates that there is  no deferences between two
age groups (P=0.261) (Figure3). Average numbers
of GPDH in age group over 50 is 23.3 ± 2.6 and in
age group under 50 it is 23.6 ± 2.8 which indicates
that there is no sign of  statistical deference
(P=0.76).
The ratio of existing  hTERT , in stage I
(18.3 ± 1.1), stage II ( 17.2 ± 3) and stage III (20.8 ±
6.9), even though there is more hTERT in stageIII,
but there is no  statistical deferences here (P=0.1) (
Figure 4).
Descriptive data of all samples of the
Cancer Patients, at stage one, 2 cases (% 4.4), at
stage two, 25 cases (% 55.6) at stage three, 18 cases
(% 40) are shown (Table2).
A receiver operating characteristic curve
(ROC) was developed to evaluate the diagnostic
performance of hTERT gene. Each unique hTERT
value was used as a cut point to calculate
sensitivity and specificity values defining the
curve and the area under the curve (AUC) and
95% CI for the area (Table3). The point of the best
cut-off value was at >18.2 where sensitivity was 60
and specificity was 57.8 (Figure 5). The area under
the ROC curve (AUC) was 0.555( Figure 6).
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Table 3. Area under the ROC curve (AUC)
0.555 Area under the ROC curve (AUC
0.0616 Standard Error
0.447 to 0.660 95% Confidence interval
0.894 Z statistic
0.3714 Significance level P (Area = 0.5)
Interpretation of results was done using
the comparative CT method for quantitation
according to this arithmetic formulas:
ΔCT= C





 = 2 - Δ ct
The mean  total in Cancer Groups 20273 ±
135993   and in control group it is 91 ± 601 which
shown that there is no deference between two
groups. (p=0.322).
The average stage in 2 person is  0.0084 ±
0.0062, in 25person 0.11 ± 0.17 and in 18 person
50681.7 ± 215024 wich shown no statistical
deferences among them (P=0. 483). The mean age
group on 29 person from under 50 is  0.0934 ±
0.16737 and on 16 person from over 50 is 57017 ±
228067.2 which proves that there is no meaningfull
diferences between two groups (P=0.181). The
average quantity on 11 of patients without  0.12 ±
0.25 and on 34 of the patients have 26831.5 ± 156453
that there is no statistical deferences between two
groups (p=0.575).
DISCUSSION
Breast cancer is the most common cancer
in women the world. So to reduce mortality from
breast cancer, the development of new methods
for the treatment, prevention or diagnosis of breast
cancer is essential26.
Telomerase is a ribonucleoprotein enzyme
consisting of two parts. The first part, subunit
active catalytic protein, hTERT  reverse
transcriptase activity that adds telomere repeated
sequences to the ends of the chromosomes and
that is essential to the continued growth of tumor
cells. hTERT gene is increasingly amplified in
human tumors and tumor cell lines.
The secondary part of the template RNA
in humans is called hTR and used as a template for
telomere synthesis. Telomerase is an therapy target
for ideal anticancer because of its activities in more
than 90 % of human cancers, there are including
more than 95 % breast cancer, , whereas most
somatic cells are indistinguishable27.
Some studies concerning amplification of
hTERT gene has been associated with cancer cell
lines. For example , according to the study U.S.
researchers amplification of  the hTERT gene  was
observed in 31 % the tumor cell , and 30 % primary
tumors , 8 of 21 lung tumors, 3  of 10 cervical tumors,
5 of 19 breast cancer and 1 of 18 neuroblastomas.
In addition, 50% cell lines and 22% primary tumors
displayed of hTERT gene copies with 4-3 copies
cell, The present findings suggest that hTERT
locus may be target for amplification during
tumorigenesis and probably, genetic events may
help to regulate telomerase activity in human
tumors28.
Ying and colleagues studies, amplification
of  hTERT gene was observed in cell lines tumors
and various human cancers, as well as a mechanism
of telomerase activation is introduced. It is
remarkable that telomerase activity increases in
both of the primary cells and cancer29.
 Thomas and his colleagues, have also
concluded the amplification of hTERT gene in
Lanfobelastic acute leukemia (ALL) and non
Lanfobelastic leukemia (ANLL). Quantitative
analysis showed that leukemia cells have many
numbers of the copies of hTERT, hTERC are normal
PBL. The results indicate that telomerase activity
in leukemia cells is associated with amplification
of hTERT gene, hTERC30.
Top of Form
According to studies conducted by
Knvutila and colleagues, amplification in both of
the hTERT and TERC gene occurs in the majority
of human cancers31.
In various studies, 25-31% of the cell line
was examined. Copies of hTERT gene were shown
in 5 d” of cell. The observed cell line was derived
of the norobelasma, breast cancer carcinoma,
cervical cancer and lung cancer. In the bladder cell
line and  Epidermal carcinoma 3 d” copies of hTERT
has been reported31.
In primary tumors, increasing of the
copies number hTERT identified  in 12%
norobelasma, 42% embryonal tumors (CNS), 22%
Hpatocellular carcinoma, 30-63% lung cancer, , 24-
30% of cervical cancers, 26% of breast cancers
J PURE APPL MICROBIO, 10(1), MARCH 2016.
380 OSOLI et al.:  STUDY OF THE hTERT AMPLIFICATION AS A PROGNOSTIC MARKER
and 48% of colon cancer. Further analysis of the
2.6 copies number of hTERT is shown in leukemia
cells31.
Zhang and colleagues Saretzki have been
reported a link between two TERT genes and
telomerase activity in multiple cell line and primary
tumors, the study Palmqvist primary tumors of
samples and other studies of the stability of human
breast epithelial cells and human foreskin
fibroblasts (Cao et al. unpublished, 2007) no
correlation were not observed between the copies
number of hTERT genes and telomerase activity.
No relationship could be observed a complex the
telomerase enzyme, consisting of components and
multiple evidence, telomerase activity is limited to
the level two components (hTERT and hTR)32.
In a variety of tumors, increasing the copy
number of the TERT has clinical relevance and
prognosis For example, Zhu and his colleagues
have shown that Lung Cancer Patients with
increased amplification of hTERT with reoccurs
will not last long.  In melanoma, copies of increased
amplification of hTERT correlated to subunits of
melanoma and era of metastasis. Also the research
shows that, Amplefication of hTRET in different
cell line normally is independent of telomerase
activities31.
Richard and his colleagues  in 2005  to
increase the hTERT gene  copy number in samples
from 64 colorectal carcinomas  were reviewed and
increased copy number(>= 3  hTERT gene copies/
nucleus)  were observed in 31(48%) cases. No
correlation was found between  hTERT gene  copy
number and hTERT RNA expression or telomerase
activity. Data show increase in copy number of the
hTERT gene in colorectal carcinoma was the result
of unstable telomerase activity levels was not
associated33.
In 2008, based on studies in Russia, the
hTERT DNA copy number of the 33 studied tumors
compared to normal tissues was unchanged. Similar
results was achieved with squamous cell cervical
carcinomas (SCC) cell lines in human papillom
virus(HPV)genomes.However, the activation of
hTERT expression was discovered in 80% of cases
(37/46, p<0.001). There was no relationship between
the  degree of mRNA increase and the tumor size
and/or prevalence metastases. No hTERT gene
expression was  shown  in 20% of cases(9/46),
while the control GAPDH expression has remained
unchanged.   The conclusion was that, the frequent
activation of  hTERT expression in SCC is not  linked
with gene amplification34.
Our current studies on results of
amplification hTERT gene, in comprising tumors
samples with non-tumors is indication of early
prognosis in primary breast cancer patients. While
amplification of hTERT gene  in breast cancer
patients compared to the control group indicates
that there is no statistical deference’s between them
and it  couldn’t be considered as prognosis factor
for the primary breast cancer patients.
According to conducted  research it
could be suggested that the hTERT gene may be
promoted through telomerase activity, but
increasing the copy number in various tumor cell
line is not always dependent on telomerase activity
and  it likely could have an independent activity.
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